Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...
November 03, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising...
October 06, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and...
September 24, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and...
August 14, 2025 16:01 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study...
August 07, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science and...
July 29, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of...
July 21, 2025 13:47 ET | Source: Daré Bioscience, Inc.

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be...
July 21, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be...
July 14, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority,...